How to Improve Access to Expertise in Cancer Imaging
Practical steps to improve situation in the context of changing landscape of cancer imaging
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
FDA Approves Ramucirumab for Hepatocellular Carcinoma
Approval is based on results from the REACH‑2 study
EMA Recommends Granting a Marketing Authorisation for New Biosimilar Pegfilgrastim
Grasustek received a positive opinion for prophylaxis against neutropenia in adult patients treated with cytotoxic chemotherapy
FDA Approves Ado-trastuzumab Emtansine for Early Breast Cancer
It is indicated in the adjuvant treatment of patients with HER2-positive tumours who have residual invasive disease after pre-operative systemic treatment
EMA is Updating the Prescribing Information for Lapatinib
Re-analysis of data on use of breast cancer medicine lapatinib following treatment with trastuzumab
EMA Recommends Refusal of a Marketing Authorisation for Cabazitaxel Teva
Developed as a hybrid medicine, it was expected to be used for treatment of prostate cancer
FDA Approves Ivosidenib as First-Line Treatment for AML with IDH1 Mutation
It is approved in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy
Patients aged 75-79 years at higher risk of distant recurrence than patients aged 70-74 years in the older population (>70 years) of patients with early stage breast cancer despite higher competing mortality
Risk of recurrence and competing mortality in older patients
EMA Recommends an Extension of Therapeutic Indication for Olaparib
New indication concerns maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian cancer
De-escalation of Commonly Used Bone-Treating Agents Is A Reasonable Treatment Option for Patients with Bone Metastases from Breast Cancer
The frequency of administration of bone-treating agents did not affect Quality of Life outcomes
Molecular Analysis of Samples from the AURORA Programme Is Underway
Integrated molecular analyses shed light on alterations correlated with disease progression and therapeutic resistance in metastatic breast cancer
EMA Recommends Granting a Conditional Marketing Authorisation for Cemiplimab
It is indicated for the treatment of advanced cutaneous squamous cell carcinoma